Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation

Atherosclerosis

Volumn 194, Issue 1, 2007, Pages 62-70

  Luchtefeld, Maren ^a   Bandlow, Nele ^a   Tietge, Uwe J F ^b   Grote, Karsten ^a   Pfeilschifter, Josef ^c   Kaszkin, Marietta ^c   Beck, Sabine ^c   Drexler, Helmut ^a   Schieffer, Bernhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Angiotensin II; oxLDL; Phospholipase A2; Smooth muscle cells

Indexed keywords

ALKADIENE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBODY; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN; LY 311727; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; TYPE IIA SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA MEDIA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; BLOOD VESSEL WALL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; LIPID PEROXIDATION; LIPID STORAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; BIPHENYL COMPOUNDS; CELLS, CULTURED; CORONARY ARTERY DISEASE; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; HYPERTENSION; INDOLES; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LOSARTAN; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; TETRAZOLES;

EID: 34648858602     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.09.024     Document Type: Article

References (61)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 8 (2002) 1211-1217
3. Six D.A., and Dennis E.A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 1488 (2000) 1-19
4. Boekholdt S.M., Keller T.T., Wareham N.J., et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 25 (2005) 839-846 Epub 2005 February 2003
5. Fichtlscherer S., Kaszkin M., Breuer S., Dimmeler S., and Zeiher A.M. Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease. Clin Sci (Lond) 106 (2004) 511-517
6. Kugiyama K., Ota Y., Takazoe K., et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 100 (1999) 1280-1284
7. Ivandic B., Castellani L.W., Wang X.P., et al. Role of group II secretory phospholipase A2 in atherosclerosis. 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 19 (1999) 1284-1290
8. Tietge U.J., Pratico D., Ding T., et al. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res 46 (2005) 1604-1614 Epub 2005 May 1616
9. Hurt-Camejo E., Camejo G., Peilot H., Oorni K., and Kovanen P. Phospholipase A(2) in vascular disease. Circ Res 89 (2001) 298-304
10. Mangin Jr. E.L., Kugiyama K., Nguy J.H., Kerns S.A., and Henry P.D. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res 72 (1993) 161-166
11. Hakala J.K., Oorni K., Ala-Korpela M., and Kovanen P.T. Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin. Arterioscler Thromb Vasc Biol 19 (1999) 1276-1283
12. Kim J.A., Gu J.L., Natarajan R., Berliner J.A., and Nadler J.L. A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II. Arterioscler Thromb Vasc Biol 15 (1995) 942-948
13. Neuzil J., Upston J.M., Witting P.K., Scott K.F., and Stocker R. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins. Biochemistry 37 (1998) 9203-9210
14. Sartipy P., Camejo G., Svensson L., and Hurt-Camejo E. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 274 (1999) 25913-25920
15. Keidar S., Attias J., Smith J., Breslow J.L., and Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 236 (1997) 622-625
16. Li Z., Iwai M., Wu L., et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 44 (2004) 758-763 Epub 2004 Sep 2027
17. Strawn W.B., Chappell M.C., Dean R.H., Kivlighn S., and Ferrario C.M. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 101 (2000) 1586-1593
18. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
19. Keidar S., Kaplan M., Hoffman A., and Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 115 (1995) 201-215
20. Beck S., Lambeau G., Scholz-Pedretti K., et al. Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation. J Biol Chem 278 (2003) 29799-29812. Epub 22003 Jun 29792
21. Snyder D.W., Bach N.J., Dillard R.D., et al. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther 288 (1999) 1117-1124
22. Schevitz R.W., Bach N.J., Carlson D.G., et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol 2 (1995) 458-465
23. Schieffer B., Luchtefeld M., Braun S., et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 87 (2000) 1195-1201
24. Luchtefeld M., Drexler H., and Schieffer B. 5-Lipoxygenase is involved in the angiotensin II-induced NAD(P)H-oxidase activation. Biochem Biophys Res Commun 308 (2003) 668-672
25. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
26. Locher R., Brandes R.P., Vetter W., and Barton M. Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases. Hypertension 39 (2002) 645-650
27. Esterbauer H., Striegl G., Puhl H., and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6 (1989) 67-75
28. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11 (1991) 81-128
29. Holvoet P., Mertens A., Verhamme P., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21 (2001) 844-848
30. Schieffer B., Bunte C., Witte J., et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 362-368
31. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 344 (1994) 793-795
32. Navalkar S., Parthasarathy S., Santanam N., and Khan B.V. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 37 (2001) 440-444
33. Ross R., Glomset J., and Harker L. Response to injury and atherogenesis. Am J Pathol 86 (1977) 675-684
34. Stary H.C., Chandler A.B., Glagov S., et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 14 (1994) 840-856
35. Khan B.V., Navalkar S., Khan Q.A., Rahman S.T., and Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 38 (2001) 1662-1667
36. Zafari A.M., Ushio-Fukai M., Minieri C.A., et al. Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxid Redox Signal 1 (1999) 167-179
37. Shiose A., and Sumimoto H. Arachidonic acid and phosphorylation synergistically induce a conformational change of p47phox to activate the phagocyte NADPH oxidase. J Biol Chem 275 (2000) 13793-13801
38. Rao G.N., Lassegue B., Alexander R.W., and Griendling K.K. Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A2 in vascular smooth-muscle cells. Biochem J 299 (1994) 197-201
39. Mukhopadhyay C.K., Ehrenwald E., and Fox P.L. Ceruloplasmin enhances smooth muscle cell- and endothelial cell-mediated low density lipoprotein oxidation by a superoxide-dependent mechanism. J Biol Chem 271 (1996) 14773-14778
40. Inoue N., Kawashima S., Hirata K.I., et al. Stretch force on vascular smooth muscle cells enhances oxidation of LDL via superoxide production. Am J Physiol 274 (1998) H1928-H1932
41. Heinecke J.W., Baker L., Rosen H., and Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest 77 (1986) 757-761
42. Balsinde J., Barbour S.E., Bianco I.D., and Dennis E.A. Arachidonic acid mobilization in P388D1 macrophages is controlled by two distinct Ca(2+)-dependent phospholipase A2 enzymes. Proc Natl Acad Sci USA 91 (1994) 11060-11064
43. Balboa M.A., Balsinde J., Winstead M.V., Tischfield J.A., and Dennis E.A. Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages. J Biol Chem 271 (1996) 32381-32384
44. Kuwata H., Nakatani Y., Murakami M., and Kudo I. Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J Biol Chem 273 (1998) 1733-1740
45. Balsinde J., Balboa M.A., and Dennis E.A. Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc Natl Acad Sci USA 95 (1998) 7951-7956
46. Balsinde J., and Dennis E.A. Distinct roles in signal transduction for each of the phospholipase A2 enzymes present in P388D1 macrophages. J Biol Chem 271 (1996) 6758-6765
47. Kudo I., Murakami M., Hara S., and Inoue K. Mammalian non-pancreatic phospholipases A2. Biochim Biophys Acta 1170 (1993) 217-231
48. Murakami M., Kudo I., and Inoue K. Secretory phospholipases A2. J Lipid Mediat Cell Signal 12 (1995) 119-130
49. Seshiah P.N., Weber D.S., Rocic P., et al. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91 (2002) 406-413
50. Chang J., Musser J.H., and McGregor H. Phospholipase A2: function and pharmacological regulation. Biochem Pharmacol 36 (1987) 2429-2436
51. Nakano T., Ohara O., Teraoka H., and Arita H. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett 261 (1990) 171-174
52. Jaross W., Eckey R., and Menschikowski M. Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest 32 (2002) 383-393
53. Talvinen K.A., Kemppainen E.A., and Nevalainen T.J. Expression of group II phospholipase A2 in the liver in acute pancreatitis. Scand J Gastroenterol 36 (2001) 1217-1221
54. Hurt-Camejo E., Andersen S., Standal R., et al. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. Arterioscler Thromb Vasc Biol 17 (1997) 300-309
55. Jaulmes A., Janvier B., Andreani M., and Raymondjean M. Autocrine and paracrine transcriptional regulation of type IIA secretory phospholipase A2 gene in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 31 (2005) 31
56. Schiering A., Menschikowski M., Mueller E., and Jaross W. Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis. Atherosclerosis 144 (1999) 73-78
57. Suzuki N., Ishizaki J., Yokota Y., et al. Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A(2)s. J Biol Chem 275 (2000) 5785-5793
58. Tischfield J.A. A reassessment of the low molecular weight phospholipase A2 gene family in mammals. J Biol Chem 272 (1997) 17247-17250
59. Valentin E., Ghomashchi F., Gelb M.H., Lazdunski M., and Lambeau G. On the diversity of secreted phospholipases A(2). Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes. J Biol Chem 274 (1999) 31195-31202
60. Valentin E., Koduri R.S., Scimeca J.C., et al. Cloning and recombinant expression of a novel mouse-secreted phospholipase A2. J Biol Chem 274 (1999) 19152-19160
61. Rosengren B., Peilot H., Umaerus M., et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler Thromb Vasc Biol 26 (2006) 1579-1585